Morgan Stanley raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $81 from $75 and keeps an Overweight rating on the shares. For volixibat, which the firm believes “could drive the next wave of growth,” it expects focus to be on comments related to Phase 2b Primary Sclerosing Cholangitis data expected in Q2 of 2026 and the Phase 2b study in Primary Biliary Cholangitis that is expected to complete enrollment next year, the analyst tells investors in a preview.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals initiated with a Buy at TD Cowen
- Mirum Pharmaceuticals: Strong Buy Rating Backed by Robust Rare Disease Portfolio and Promising Growth Prospects
- Mirum Pharmaceuticals price target raised to $77 from $53 at JPMorgan
- Mirum Pharmaceuticals completes enrollment in VISTAS study of volixibat
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment